Taprenepag

DB12623InvestigationalSmall molecule

Taprenepag has been used in trials studying the treatment of Ocular Hypertension and Glaucoma, Open-Angle.

Chemical structure of Taprenepag
Formula / weight
C24H22N4O5S · 478.52 g/mol (avg)
Code names
CP-544326 · PF-04217329

Resolves to

Compound
UNII9CD894KUMJCAS752187-80-7ChEMBLCHEMBL2107783PubChem18376177
Structure
InChIKeyMFFBXYNKZHTCEY-UHFFFAOYSA-NSMILESOC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1
Targets
P43116PTGER2

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Taprenepag, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In